Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Inclusion Criteria: * The written informed consent of the patients has been obtained before any examination, sampling and analysis related to the study. * Primary lung adenocarcinoma diagnosed histologically/cytologically. * Stages IIIA-IIIB (N1-N2) according to the AJCC 8th edition lung cancer stage and plan to receive radical excision judged by investigators. * EGFR mutation positive (19Del or L858R, with or without T790M) * The presence of at least one measurable lesion and suitable for accurate repeated measurements. * ECOG performance status 0-1. * For premenopausal women with fertility, the result of serum or urine pregnancy test should be negative within 7 days before the first dose. Exclusion Criteria: * Squamous cell carcinoma, and tumors with neuroendocrine components such as large cell carcinoma, or small cell carcinoma. * Patients with EGFR exon 20 insertion mutation. * Exposure to other antitumor therapies prior to enrolment. * Major surgery was performed in the four weeks prior to the first dosing of the study drug. * Pregnant or lactating female patients. * Use of CYP3A4 strong depressant within 7 days or CYP3A4 strong inducer within 21 days prior to initial administration. * Have a history of or present complications with other malignancies. * Patients with severe or uncontrolled systemic disease requiring treatment were not considered suitable for the study. * ECG QT interval prolongation or associated risk. * A history of interstitial pneumonia or related risk. * Inadequate bone marrow or organ reserve. * Other circumstances that are not suitable for participation in this study.